CEO SUMMARY: On May 14, Predictive Biosciences learned that its Medicare contractor had determined that one of its three molecular tests for bladder cancer was a screening test. It also never got a determination on its other two molecular tests. Because Medicare is half of the lab’s payer mix, and since the company was worried […]
Medicare Contractor’s Ruling on MolDx Test Causes Lab to Close
Lab testing company was serving 900 urologists
- By Joseph Burns
- > From the Volume XX No. 9 - July 8, 2013 Issue
- Tags: arup lab, arup laboratories, cancer tests, cap, cap and clia, clia, clia-certified laboratory, clinical lab, Clinical Laboratory, clinical laboratory industry, cpt, cpt code, diagnostic assays, Diagnostic tests, Fee-for-service, genetic test, genetic testing, hie, lab industry, lab test, lab testing, laboratories, laboratory companies, laboratory industry, Medicare, Medicare Administrative Contractor, molecular assay, molecular assays, molecular diagnostic, molecular diagnostic assays, molecular diagnostic test, molecular testing, molecular tests, pathologists, personalized medicine, private payer, the clinical laboratory, the laboratory
